Effective A1c Reduction in Type 2 Diabetes:
A Closer Look at Combination Insulin Therapy

A continuing medical education activity sponsored by NAMCP and AAMCN.

This activity is an archive from the webinars held April 6, 2016 and April 13, 2016. If you participated in the live webinars, you are not eligible for continuing education credits from this archive.

This activity is valid from May 25, 2016 to May 31, 2018

Instructions for CME/CNE: Listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. A score of 70% must be achieved on the post test to receive continuing education credits. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

These presentations require Adobe Flash Player.  You can download it here.

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This presentation is supported by an educational grant from Sanofi US




According to the CDC, uncontrolled type 2 DM doubles a personís risk for death, and on average individuals with type 2 DM lose 10-15 years of life. The management of type 2 DM remains a major challenge as many patients continue to struggle with achieving therapeutic goals, including control of A1C level, blood pressure, cholesterol, and weight. Fortunately, recent advances in individualizing treatment through basal insulin therapy and GLP-1 analogs in Type 2 Diabetes management have given healthcare professionals the ability to shrink this clinical practice gap, particularly when they are combined.

Upon Completion of this activity, participants will be able to:

  • Analyze safety and efficacy data on current and emerging complementary combination therapies for achieving individualized glycemic and A1c target goals in types 2 diabetes

  • Review the most appropriate basal insulin and GLP-1 combination therapy taking into consideration the relationship of pharmacokinetics on pharmacodynamics effects on PPG and fixed vs free-dose combinations

  • Discuss strategies to manage hyperglycemia in type 2 diabetes patients on metformin currently unable to achieve A1c targets

  • Analyze current recommendations for risk factor modification and adding/intensifying basal insulin and GLP-1 combination therapy in appropriate patients

  • Identify strategies to overcome barriers in initiating insulin and optimizing basal insulin and GLP-1 combination therapy

  • Examine ways to improve communications between patients and providers for better management and adherence


Faculty: Tom Elasy, MD, MPH
Medical Director, Associate Professor
Vanderbilt Diabetes Center, School of Medicine


Dr. Elasy has no financial relationships to disclose.
  Planning Committee:
Bill Williams, MD has no real or perceived financial relationships to disclose.
Jacquelyn Smith, RN, BSN, MA, CMCN has no real or perceived financial relationships to disclose.
Katie Eads has no real or perceived financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category I creditsTM. Each physician should claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of continuing nursing
education by the American Nurses Credentialing Centerís Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in continuing
nursing credit.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This presentation is supported by an educational grant from Sanofi US

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.